Manuel Guzmán Selected Research

Cannabinoids

1/2023	Endocannabinoid signaling in glioma.
11/2021	Cannabinoid Cancer Biology and Prevention.
1/2019	Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration.
1/2019	Astroglial monoacylglycerol lipase controls mutant huntingtin-induced damage of striatal neurons.
11/2018	Appraising the "entourage effect": Antitumor action of a pure cannabinoid versus a botanical drug preparation in preclinical models of breast cancer.
11/2018	Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma.
11/2018	Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide.
1/2017	Cannabinoid Type-2 Receptor Drives Neurogenesis and Improves Functional Outcome After Stroke.
1/2015	Endocannabinoids and Cancer.
8/2014	Targeting CB2-GPR55 receptor heteromers modulates cancer cell signaling.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Manuel Guzmán Research Topics

Disease

37	Neoplasms (Cancer) 01/2023 - 01/2003
20	Glioma (Gliomas) 01/2023 - 04/2002
8	Huntington Disease (Huntington's Disease) 01/2020 - 11/2009
8	Breast Neoplasms (Breast Cancer) 01/2019 - 07/2006
6	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2021 - 04/2007
5	Glioblastoma (Glioblastoma Multiforme) 03/2008 - 08/2004
4	Neoplasm Metastasis (Metastasis) 01/2016 - 04/2006
3	Neuroinflammatory Diseases 01/2019 - 01/2008
3	Abdominal Obesity 08/2015 - 01/2008
3	Obesity 10/2011 - 06/2003
2	Parkinson Disease (Parkinson's Disease) 11/2021 - 08/2011
2	Ataxia (Dyssynergia) 12/2020 - 01/2019
2	Cognitive Dysfunction 01/2020 - 02/2005
2	Nervous System Diseases (Neurological Disorders) 01/2020 - 08/2007
2	Triple Negative Breast Neoplasms 11/2018 - 01/2016
2	Malformations of Cortical Development 01/2018 - 11/2017
2	Stroke (Strokes) 01/2017 - 04/2007
2	Cardiovascular Diseases (Cardiovascular Disease) 07/2014 - 08/2013
2	Infections 03/2014 - 12/2013
2	Rheumatoid Arthritis 03/2014 - 06/2005
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 09/2012 - 01/2008
2	Disease Progression 08/2011 - 01/2011
2	Melanoma (Melanoma, Malignant) 07/2009 - 12/2006
2	Multiple Sclerosis 05/2008 - 04/2007
2	Brain Injuries (Brain Injury) 08/2007 - 04/2007
2	Chronic Renal Insufficiency 10/2003 - 02/2003
2	Atrial Fibrillation 10/2003 - 02/2003
1	Oropharyngeal Neoplasms 11/2021
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 11/2021
1	Demyelinating Diseases (Demyelinating Disease) 01/2021
1	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 11/2020
1	Niemann-Pick Diseases (Niemann Pick Disease) 11/2020
1	Gliosis 01/2019
1	Dry Eye Syndromes (Dry Eye Syndrome) 04/2018
1	Focal Cortical Dysplasia 01/2018
1	Megalencephaly 01/2018
1	Hemimegalencephaly 01/2018
1	Classical Lissencephalies and Subcortical Band Heterotopias 11/2017
1	Drug Resistant Epilepsy 11/2017
1	Infarction (Infarctions) 01/2017
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2017

Drug/Important Bio-Agent (IBA)

41	CannabinoidsIBA 01/2023 - 04/2002
18	Dronabinol (THC)FDA LinkGeneric 12/2020 - 04/2002
15	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2023 - 01/2003
11	EndocannabinoidsIBA 01/2023 - 03/2007
11	CeramidesIBA 11/2016 - 04/2002
5	Proteins (Proteins, Gene)FDA Link 11/2021 - 04/2006
5	1,1-dimethylbutyl-1-deoxy-Delta(9)-THCIBA 01/2017 - 01/2003
5	Cannabinoid Receptor AgonistsIBA 01/2011 - 12/2002
4	HDL CholesterolIBA 08/2015 - 01/2008
3	Biological ProductsIBA 01/2023 - 01/2015
3	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 11/2020 - 01/2016
3	Biomarkers (Surrogate Marker)IBA 01/2019 - 06/2015
3	Temozolomide (Temodar)FDA LinkGeneric 11/2018 - 01/2011
3	CannabidiolIBA 11/2018 - 01/2011
3	LigandsIBA 01/2016 - 10/2009
3	Triglycerides (Triacylglycerol)IBA 08/2015 - 07/2004
3	Glucose (Dextrose)FDA LinkGeneric 08/2015 - 01/2008
3	CB2 Cannabinoid ReceptorIBA 06/2015 - 07/2006
3	LipidsIBA 01/2010 - 06/2003
3	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 10/2009 - 08/2002
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2004 - 01/2003
2	Pharmaceutical PreparationsIBA 11/2018 - 07/2009
2	nabiximols (Sativex)IBA 11/2018 - 07/2016
2	Mechanistic Target of Rapamycin Complex 1IBA 01/2018 - 10/2013
2	TOR Serine-Threonine KinasesIBA 01/2018 - 07/2015
2	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2016 - 08/2014
2	LDL CholesterolIBA 08/2015 - 10/2011
2	Insulin (Novolin)FDA Link 07/2014 - 08/2013
2	CholesterolIBA 03/2014 - 10/2011
2	C-Reactive ProteinIBA 09/2012 - 10/2011
2	Fibrinogen (Factor I)FDA Link 09/2012 - 10/2011
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2011 - 01/2003
2	Matrix Metalloproteinase 2 (Gelatinase A)IBA 03/2008 - 03/2003
2	fumonisin B1IBA 03/2008 - 01/2008
2	Angiopoietin-2IBA 03/2003 - 01/2003
1	p38 Mitogen-Activated Protein KinasesIBA 11/2021
1	Antineoplastic Agents (Antineoplastics)IBA 11/2021
1	Endoplasmic Reticulum Chaperone BiPIBA 11/2021
1	glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA 01/2021
1	TrehaloseIBA 12/2020
1	DisaccharidesIBA 12/2020
1	temsirolimus FDA Link 12/2020
1	SphingolipidsIBA 11/2020
1	SphingomyelinsIBA 11/2020
1	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 11/2020
1	Histamine H3 Receptors (Histamine H3 Receptor)IBA 01/2020
1	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 01/2020
1	human ERBB2 proteinIBA 01/2019
1	JZL 184IBA 01/2019
1	antiglomerular basement membrane antibodyIBA 11/2018
1	Liposomes (Liposome)IBA 04/2018
1	Lubricant Eye Drops (Artificial Tears)IBA 04/2018
1	Adenosine (Adenocard)FDA LinkGeneric 01/2018
1	GTP-Binding Proteins (G-Protein)IBA 01/2018
1	Small Interfering RNA (siRNA)IBA 11/2017
1	pyrazoleIBA 01/2017
1	PyransIBA 01/2017

Therapy/Procedure

16	Therapeutics 01/2023 - 01/2003
2	Oral Administration 01/2019 - 11/2018